ALL-TARGET: A precision medicine randomized trial for patients with relapsed or refractory T-cell Acute Lymphoblastic Leukemia based on a functional approach

As part of the European research project ALL-TARGET (A precision medicine randomized trial for patients with relapsed or refractory T-cell Acute Lymphoblastic Leukemia), IQS plays a key role in Work Package 3 (WP3), which focuses on understanding and improving the quality of life of patients undergoing treatment for relapsed or refractory T-cell Acute Lymphoblastic Leukemia.

Working in collaboration with the Josep Carreras Leukaemia Research Institute, ALAN (Acute Leukemia Advocates Network), and the European Hematology Association, IQS leads the design and implementation of a mobile application developed specifically for patients enrolled in the study.

This app is designed to collect patient-reported outcomes and provide meaningful digital support throughout the treatment journey. By offering access to curated information and enabling patients to interact with trained moderators and cancer survivors, the app aims to foster a supportive and empathetic environment. The project explores whether integrating technology into patient care can positively impact emotional well-being and overall health outcomes.

Through this initiative, IQS contributes to advancing patient-centered innovation in precision medicine, combining its technological expertise with a humanistic approach to healthcare. By leveraging digital tools, the project seeks to empower patients, enhance communication between patients and clinicians, and improve the way we understand and support quality of life in complex clinical scenarios.